Literature DB >> 26353176

Reproducibility of an assay to measure serum progesterone metabolites that may be related to breast cancer risk using liquid chromatography-tandem mass spectrometry.

Britton Trabert, Roni T Falk, Frank Z Stanczyk, Katherine A McGlynn, Louise A Brinton, Xia Xu.   

Abstract

Recent data suggest a novel role of progesterone in breast cancer etiology involving the progesterone metabolites 3α-dihydroprogesterone (3αHP), 5α-dihydroprogesterone (5αP), and 20α-dihydroprogesterone (20αHP). Accurate and precise measures of progesterone metabolites are needed for etiologic studies of hormonally related cancers. We have developed a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method to measure five hormones, including progesterone, its precursor pregnenolone, and three progesterone metabolites, 5αP, 3αHP, and 20αHP. Hormone levels were measured in serum from 20 healthy volunteers (7 men, 5 premenopausal women, and 8 postmenopausal women). Two blinded, randomized aliquots per individual were assayed in each of four batches. The coefficients of variation (CV) and intraclass correlation coefficients (ICC) were calculated from the individual components of variance. The overall laboratory CVs were <3% and ICCs were uniformly high (>98%) for all hormones measured across sex/menopausal status groups. Our HPLC-MS/MS assay of progesterone metabolites demonstrated excellent sensitivity, laboratory reproducibility, and interindividual variation, suggesting that this serum assay is suitable for epidemiologic research. The high sensitivity of the assay, and thus the ability to quantify concentrations among postmenopausal women and men, further supports that this novel assay is suitable for studies of serum progesterone metabolite concentrations and risk of breast cancer or other hormonally related cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26353176      PMCID: PMC4966666          DOI: 10.1515/hmbci-2015-0026

Source DB:  PubMed          Journal:  Horm Mol Biol Clin Investig        ISSN: 1868-1883


  22 in total

Review 1.  Progesterone and breast cancer.

Authors:  Carol A Lange; Douglas Yee
Journal:  Womens Health (Lond)       Date:  2008-03

2.  Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk.

Authors:  Louise A Brinton; Tim J Key; Laurence N Kolonel; Karin B Michels; Howard D Sesso; Giske Ursin; Stephen K Van Den Eeden; Shannon N Wood; Roni T Falk; Dominick Parisi; Chantal Guillemette; Patrick Caron; Véronique Turcotte; Laurel A Habel; Claudine J Isaacs; Elio Riboli; Elisabete Weiderpass; Michael B Cook
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

3.  Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?

Authors:  Britton Trabert; Nicolas Wentzensen; Hannah P Yang; Mark E Sherman; Albert R Hollenbeck; Yikyung Park; Louise A Brinton
Journal:  Int J Cancer       Date:  2012-08-30       Impact factor: 7.396

4.  Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.

Authors:  Stacey A Missmer; A Heather Eliassen; Robert L Barbieri; Susan E Hankinson
Journal:  J Natl Cancer Inst       Date:  2004-12-15       Impact factor: 13.506

5.  Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort.

Authors:  Louise A Brinton; Douglas Richesson; Michael F Leitzmann; Gretchen L Gierach; Arthur Schatzkin; Traci Mouw; Albert R Hollenbeck; James V Lacey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

6.  Progesterone metabolism in adipose cells.

Authors:  Yonghua Zhang; Mélanie Nadeau; Frédérick Faucher; Odette Lescelleur; Simon Biron; Marleen Daris; Caroline Rhéaume; Van Luu-The; André Tchernof
Journal:  Mol Cell Endocrinol       Date:  2008-10-15       Impact factor: 4.102

7.  Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II.

Authors:  Janet S Hildebrand; Eric J Jacobs; Peter T Campbell; Marjorie L McCullough; Lauren R Teras; Michael J Thun; Susan M Gapstur
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-20       Impact factor: 4.254

8.  Estrogen plus progestin and colorectal cancer in postmenopausal women.

Authors:  Rowan T Chlebowski; Jean Wactawski-Wende; Cheryl Ritenbaugh; F Allan Hubbell; Joao Ascensao; Rebecca J Rodabough; Carol A Rosenberg; Victoria M Taylor; Randall Harris; Chu Chen; Lucile L Adams-Campbell; Emily White
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

9.  Menopausal hormone therapy and risk of colorectal cancer.

Authors:  Jill R Johnson; James V Lacey; Deann Lazovich; Melissa A Geller; Catherine Schairer; Arthur Schatzkin; Andrew Flood
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

10.  Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.

Authors:  Andrew W Roddam; Naomi E Allen; Paul Appleby; Timothy J Key
Journal:  J Natl Cancer Inst       Date:  2008-01-29       Impact factor: 13.506

View more
  9 in total

Review 1.  Progesterone and Breast Cancer.

Authors:  Britton Trabert; Mark E Sherman; Nagarajan Kannan; Frank Z Stanczyk
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

2.  Association of Endogenous Pregnenolone, Progesterone, and Related Metabolites with Risk of Endometrial and Ovarian Cancers in Postmenopausal Women: The BFIT Cohort.

Authors:  Louise A Brinton; Cher M Dallal; Britton Trabert; Ashley M Geczik; Doug C Bauer; Diana S M Buist; Jane A Cauley; Roni T Falk; Gretchen L Gierach; Trisha F Hue; James V Lacey; Andrea Z LaCroix; Kara A Michels; Jeffrey A Tice; Xia Xu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-08-31       Impact factor: 4.090

3.  Endogenous Progestogens and Colorectal Cancer Risk among Postmenopausal Women.

Authors:  Kara A Michels; Ashley M Geczik; Doug C Bauer; Louise A Brinton; Diana S M Buist; Jane A Cauley; Cher M Dallal; Roni T Falk; Trisha F Hue; James V Lacey; Andrea Z LaCroix; Jeffrey A Tice; Xia Xu; Britton Trabert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-04-07       Impact factor: 4.090

4.  Association of Circulating Progesterone With Breast Cancer Risk Among Postmenopausal Women.

Authors:  Britton Trabert; Doug C Bauer; Diana S M Buist; Jane A Cauley; Roni T Falk; Ashley M Geczik; Gretchen L Gierach; Manila Hada; Trisha F Hue; James V Lacey; Andrea Z LaCroix; Jeffrey A Tice; Xia Xu; Cher M Dallal; Louise A Brinton
Journal:  JAMA Netw Open       Date:  2020-04-01

Review 5.  Effects of menopausal hormone therapy-based on the role of estrogens, progestogens, and their metabolites in proliferation of breast cancer cells.

Authors:  Yu Deng; Hongyan Jin
Journal:  Cancer Biol Med       Date:  2021-11-15       Impact factor: 5.347

6.  Selection for female traits of high fertility affects male reproductive performance and alters the testicular transcriptional profile.

Authors:  Marten Michaelis; Alexander Sobczak; Dirk Koczan; Martina Langhammer; Norbert Reinsch; Jennifer Schoen; Joachim M Weitzel
Journal:  BMC Genomics       Date:  2017-11-21       Impact factor: 3.969

7.  Brain Aromatase and the Regulation of Sexual Activity in Male Mice.

Authors:  David C Brooks; John S Coon V; Cihangir M Ercan; Xia Xu; Hongxin Dong; Jon E Levine; Serdar E Bulun; Hong Zhao
Journal:  Endocrinology       Date:  2020-10-01       Impact factor: 4.736

8.  Relationship of Serum Progesterone and Progesterone Metabolites with Mammographic Breast Density and Terminal Ductal Lobular Unit Involution among Women Undergoing Diagnostic Breast Biopsy.

Authors:  Manila Hada; Hannah Oh; Shaoqi Fan; Roni T Falk; Berta Geller; Pamela Vacek; Donald Weaver; John Shepherd; Jeff Wang; Bo Fan; Sally Herschorn; Louise A Brinton; Xia Xu; Mark E Sherman; Britton Trabert; Gretchen L Gierach
Journal:  J Clin Med       Date:  2020-01-17       Impact factor: 4.241

9.  Accuracy and precision guidelines for optimal breeding time in bitches using in-house progesterone measurement compared with chemiluminescent microparticle immunoassay.

Authors:  Nutnaree Kunanusont; Darsaniya Punyadarsaniya; Sakchai Ruenphet
Journal:  Vet World       Date:  2021-03-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.